Endeavor

Next-Gen Cell Therapy Shows Lasting Remission for Older Adults with Aggressive Leukemia

Recently approved obe-cel continues to deliver high remission rates and durable responses in patients once considered too high-risk for immunotherapy

New Immunotherapy Strategy Improves Outcomes in Patients with Advanced Head and Neck Cancer

Patients treated with pembrolizumab were at least 27% less likely to experience cancer recurrence or death

Moffitt Launches Immunotherapy Podcast

Monthly series highlights visionaries in immunotherapy and the breakthroughs that are transforming lives

Business of Biotech Attracts Record Numbers

Executives, entrepreneurs, venture capitalists, angel investors and researchers from across the U.S. gather for unique opportunity to collaborate

Are Personalized Vaccines the Future of Triple-Negative Breast Cancer Treatment?

Moffitt studies the use of dendritic cell vaccines to harness the immune system

Immunotherapy May Help Prevent Acute Myeloid Leukemia Relapse After Transplant

Early phase 1 trial results indicate safety and efficacy of donor gamma delta T cell infusions

Overcoming a Rare Cancer with Determination and a Revolutionary New Therapy

After years of treatments, a first-of-its-kind cell therapy is offering new possibilities for one synovial sarcoma patient

New CAR T-Cell Therapy Shows Promising Results for Advanced Multiple Myeloma

Early trial results show high success rates and manageable side effects

Moffitt Study Explores Key Risk Factors To Better Personalize CAR T-Cell Therapy

The study analyzed ide-cel to help physicians intervene and reduce toxicities in multiple myeloma patients